Bristol Will Use Partners To Maintain Primary Care Presence
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is using a "different model," not "exiting," primary care, CEO says. Deal with Merck for diabetes compound is example of how Bristol will use partnerships going forward.
You may also be interested in...
New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting
Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.
New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting
Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.
Primary Care Sales Force Downsizing Will Continue, Bristol Says
Bristol-Myers Squibb expects additional downsizing of its primary care sales force as it shifts its product portfolio to specialty care, Exec VP Donald Hayden told analysts July 29